Literature DB >> 9846894

Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules.

C González1, G Farías, R B Maccioni.   

Abstract

The microtubule associated protein tau is the main structural component of paired helical filaments (PHFs), aberrant polymers found intracellularly in neurons of brains with the Alzheimer's disease. Glycation is one of the posttranslational modifications that has been found in tau from PHFs, but not in normal brain tau. Studies were carried out with purified tau protein subjected to chemical modifications, in order to further investigate the mechanisms of tau self-association into PHFs. Tau was subjected to modifications affecting reactive lysyl residues, e.g., carbamoylation with potassium cyanate and glycation reaction with glucose. The effects of these modifications to produce functional alterations in tau capacity to bind brain tubulin and to induce microtubule assembly were investigated. Chemically-modified tau and tau of Alzheimer's type exhibited a similar microtubule interaction behavior as analysed by overlay assays, but those were different than normal tau controls. On the other hand, studies of the microtubule assembly kinetics indicated that the reported tau modifications resulted in a loss of its capacity to promote microtubule assembly from purified tubulin preparations. The data on the differences in the electrophoretic profiles, Western blots and the overlay patterns, along with those on the microtubule polymerisation of normal brain tau as compared with both modified and Alzheimer's tau, suggest changes in the functional behavior of this protein as a result of its structural modifications. These studies were complemented with an immunogold analysis at the electron microscope level, which indicated that the modified tau did not incorporate into assembled microtubules. These findings, combined with the results on tau chemical modifications suggest that the reactive lysine residues within functional domains on tau, e.g., those of the repetitive binding motifs, were affected by these modifications. Furthermore, these observations provide new clues to understand the anomalous interactions of tau in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846894

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  7 in total

1.  On the biomarkers and mechanisms of konzo, a distinct upper motor neuron disease associated with food (cassava) cyanogenic exposure.

Authors:  Roman M Kassa; Nyamabo L Kasensa; Victor H Monterroso; Robert J Kayton; John E Klimek; Larry L David; Kalala R Lunganza; Kazadi T Kayembe; Marina Bentivoglio; Sharon L Juliano; Desire D Tshala-Katumbay
Journal:  Food Chem Toxicol       Date:  2010-06-09       Impact factor: 6.023

2.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 3.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

4.  D-Ribosylated Tau forms globular aggregates with high cytotoxicity.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  Cell Mol Life Sci       Date:  2009-06-11       Impact factor: 9.261

Review 5.  Oxidative stress in Alzheimer disease.

Authors:  Alejandro Gella; Nuria Durany
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

6.  Porcine brain extract promotes osteogenic differentiation of bone marrow derived mesenchymal stem cells and bone consolidation in a rat distraction osteogenesis model.

Authors:  Jia Xu; Yuxin Sun; Tianyi Wu; Bin Wang; Yang Liu; Jinfang Zhang; Wayne Yukwai Lee; Qinglin Kang; Yimin Chai; Gang Li
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

Review 7.  Antioxidant therapies for Alzheimer's disease.

Authors:  Ye Feng; Xiaochuan Wang
Journal:  Oxid Med Cell Longev       Date:  2012-07-25       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.